{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-013212","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2022-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.315476+00:00","generated_at":"2026-06-24T08:18:00.196098+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Terns appoints Dr. Radhika Tripuraneni to board of directors","bullets":["Dr. Tripuraneni appointed as Class II director and Audit Committee member effective July 26, 2022.","She is Chief Development Officer of Prothena Corporation plc with over 15 years of drug development experience.","No material transaction or arrangement exists with Dr. Tripuraneni or any related party."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-013212","json":"https://secwatch.observer/filing/0000950170-22-013212.json","markdown":"https://secwatch.observer/filing/0000950170-22-013212.md","text":"https://secwatch.observer/filing/0000950170-22-013212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022013212/0000950170-22-013212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022013212/tern-20220726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:18:00.196098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"acbd8bc349","claim":"Radhika Tripuraneni was appointed as Director at Terns Pharmaceuticals, Inc..","evidence_excerpt":"On July 26, 2022, the Board of Directors (the “Board”) of Terns Pharmaceuticals, Inc. (the “Company”) appointed Radhika Tripuraneni, M.D., M.P.H. to serve as a Class II director until her successor is duly elected and qualified or until her earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022013212/0000950170-22-013212-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}